<DOC>
	<DOCNO>NCT01077375</DOCNO>
	<brief_summary>The objective study evaluate safety , tolerability efficacy milnacipran patient inadequate response duloxetine treatment fibromyalgia .</brief_summary>
	<brief_title>Study Milnacipran Patients With Inadequate Response Duloxetine Treatment Fibromyalgia</brief_title>
	<detailed_description>- Two week Duloxetine 60 mg Open-Label Period - Randomization Double-Blind Treatment Period : 10 week Milnacipran ( direct switch ) 10 week placebo ( one week blind 30 mg duloxetine ) - One week Double-Blind Down-Taper Period</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Diagnosis fibromyalgia Have treat stable dosage duloxetine ( 60 mg/day ) ≥ 4 week immediately Screening ( Visit 1 ) Duloxetine must prescribe treatment Fibromyalgia Have VAS 1week pain recall score ≥ 40 mm ≤ 90 mm At Visit 2 , eligible enter randomize treatment period , must continue VAS 1week pain recall score ≥ 40 mm dissatisfy current Duloxetine treatment . Suicidal risk History mania , bipolar disorder , psychotic disorder , schizophrenia , current episode major depressive disorder Myocardial infarction and/or stroke within prior 6 month Systolic blood pressure &gt; 160 mm Hg mean diastolic blood pressure &gt; 100 mm Hg Screening ( Visit 1 ) Substance abuse Pulmonary dysfunction Severe renal impairment Active cardiac disease Liver disease Uncontrolled narrowangle glaucoma Autoimmune disease Cancer Inflammatory bowel disease Unstable endocrine disease Prostatic enlargement Female patient pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Milnacipran</keyword>
	<keyword>Duloxetine</keyword>
	<keyword>Switch</keyword>
	<keyword>Forest Research Institute</keyword>
</DOC>